#United States #San Francisco #Prostate Cancer #Blue Earth Diagnostics #POSLUMA

Blue Earth Diagnostics at ASCO 2026 Genitourinary Symposium

Blue Earth Diagnostics, a subsidiary of Bracco and a leader in PET radiopharmaceuticals, is set to present groundbreaking research on POSLUMA® (flotufolastat F 18) at the upcoming ASCO 2026 Genitourinary Cancer Symposium. This prestigious conference will take place from February 26 to 28, 2026 in San Francisco, California.

Presentations Overview

The focus of the presentations will be the results from a first-of-its-kind intra-patient study comparing urinary radioactivity between POSLUMA and another PET agent, piflufolastat F 18. This study specifically targets men experiencing low prostate-specific antigen (PSA) biochemical recurrence following radical prostatectomy. Additionally, a variety of post-hoc analyses from pivotal clinical trials, including the Phase 3 SPOTLIGHT and LIGHTHOUSE studies, will be included, shedding light on the diagnostic efficiency of 18F-flotufolastat PET/CT for men with suspected biochemical recurrence or newly diagnosed prostate cancer.

Presentations will consist of:

• - Analyses comparing the diagnostic performance of PET/CT with conventional imaging methods, focusing on specific anatomical sites.
• - Evaluating the detection capabilities for pelvic lymph node metastases and bone metastases using 18F-flotufolastat.

Company's Commitment to Innovation

Marco Campione, President and CEO of Blue Earth Diagnostics, expressed his enthusiasm about sharing this novel data, stating, "We're pleased to provide deeper insights into the operational efficacy of POSLUMA across vital prostate cancer contexts. Our findings underscore our dedication to promoting molecular imaging backed by solid evidence that can enhance clinical decisions—especially in circumstances where early or clearer detection can significantly impact patient care."

This commitment to evidence-based medical innovation aligns with Blue Earth Diagnostics’ overarching goal: transforming molecular imaging to meet the dynamic needs of the oncology community. The organization constantly aims to foster engagement and dialogue, highlighting the importance of such findings within the evolving landscape of cancer diagnostics.

Participation and Engagement

For those attending the ASCO GU event, Blue Earth Diagnostics encourages participation in their sessions where detailed discussions on these scientific findings will occur. Additionally, attendees can visit Booth #15 to engage further and inquire about the company's expanding portfolio of innovative radiopharmaceuticals.

Moderated poster presentation sessions are scheduled for February 26 at 11:30 AM - 12:45 PM and 5:45 PM - 6:45 PM (PST), with options for on-demand viewing as well.

About Blue Earth Diagnostics

Established in 2014, Blue Earth Diagnostics specializes in the development and commercialization of PET radiopharmaceuticals, focused mainly on cancer diagnostics. The company continues to expand its international footprint and enhance its product offerings aimed at providing vital diagnostic solutions for various disease states. Emphasizing innovation, more than 9% of revenues have been reinvested into research and development initiatives aimed at enhancing imaging diagnostics and medical devices.

In conclusion, the ASCO 2026 Symposium promises to be an invaluable platform for Blue Earth Diagnostics to illustrate advancements in prostate cancer diagnostics through the lens of its cutting-edge radiopharmaceuticals, with POSLUMA standing at the forefront of these efforts.